GlucoTrack (GCTK) 10-Q2022 Q2 Quarterly report

Filed: 15 Aug 22, 10:50am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: AI, analytic, anonymized, app, architecture, attractive, battery, bench, beta, Bluetooth, cabled, capturing, case, CGM, Chair, clearance, collected, costly, cybersecurity, Director, ear, Europe, facilitate, faster, hardware, healthy, human, lab, learning, led, leverage, machine, main, maintaining, Middle, mobile, multiple, patient, pharma, pivotal, point, precursor, prototype, Rabin, reduction, release, sensing, shed, simplified, simulated, smallest, stability, storage, stored, stream, tablet, transfer, underwent, upcoming, utilized, validating, valuable, version, wired

Removed: build, building, carried, clear, consistency, continuing, Contract, CRO, develop, developed, distribution, enhancement, entrance, European, facility, field, forming, founded, German, greater, half, home, identifying, immaterial, increased, industry, interviewing, introducing, located, MedTech, mission, model, organizational, paired, performed, planning, private, produce, ready, receiving, reclassified, recruiting, reimbursement, roadmap, role, Science, serve, shareholder, team, University, working

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

GCTK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the “Company”) for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Paul Goode
		Paul Goode
		Principal Executive Officer

	Dated: August 15, 2022

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the “Company”) for the period ended June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jolie Kahn, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)	the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:	/s/ Jolie Kahn
		Jolie Kahn
		Principal Financial Officer

	Dated: August 15, 2022

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.